Human B-Raf Kinase Domain in Complex with an Bromopyridine Benzamide Inhibitor

Experimental Data Snapshot

  • Resolution: 3.40 Å
  • R-Value Free: 0.307 
  • R-Value Work: 0.241 
  • R-Value Observed: 0.244 

wwPDB Validation   3D Report Full Report

Ligand Structure Quality Assessment 

This is version 1.4 of the entry. See complete history


Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors.

Wenglowsky, S.Ren, L.Ahrendt, K.A.Laird, E.R.Aliagas, I.Alicke, B.Buckmelter, A.J.Choo, E.F.Dinkel, V.Feng, B.Gloor, S.L.Gould, S.E.Gross, S.Gunzner-Toste, J.Hansen, J.D.Hatzivassiliou, G.Liu, B.Malesky, K.Mathieu, S.Newhouse, B.Raddatz, N.J.Ran, Y.Rana, S.Randolph, N.Risom, T.Rudolph, J.Savage, S.Selby, L.T.Shrag, M.Song, K.Sturgis, H.L.Voegtli, W.C.Wen, Z.Willis, B.S.Woessner, R.D.Wu, W.I.Young, W.B.Grina, J.

(2011) ACS Med Chem Lett 2: 342-347

  • DOI: https://doi.org/10.1021/ml200025q
  • Primary Citation of Related Structures:  
    3TV4, 3TV6

  • PubMed Abstract: 

    The V600E mutation of B-Raf kinase results in constitutive activation of the MAPK signaling pathway and is present in approximately 7% of all cancers. Using structure-based design, a novel series of pyrazolopyridine inhibitors of B-Raf(V600E) was developed. Optimization led to the identification of 3-methoxy pyrazolopyridines 17 and 19, potent, selective, and orally bioavailable agents that inhibited tumor growth in a mouse xenograft model driven by B-Raf(V600E) with no effect on body weight. On the basis of their in vivo efficacy and preliminary safety profiles, 17 and 19 were selected for further preclinical evaluation.

  • Organizational Affiliation

    Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States.

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Serine/threonine-protein kinase B-raf
A, B
307Homo sapiensMutation(s): 0 
UniProt & NIH Common Fund Data Resources
Find proteins for P15056 (Homo sapiens)
Explore P15056 
Go to UniProtKB:  P15056
PHAROS:  P15056
GTEx:  ENSG00000157764 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP15056
Sequence Annotations
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
Query on TV4

Download Ideal Coordinates CCD File 
C [auth A],
D [auth B]
C15 H15 Br F2 N4 O3 S
Binding Affinity Annotations 
IDSourceBinding Affinity
TV4 BindingDB:  3TV4 IC50: min: 110, max: 1200 (nM) from 3 assay(s)
PDBBind:  3TV4 IC50: 110 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Resolution: 3.40 Å
  • R-Value Free: 0.307 
  • R-Value Work: 0.241 
  • R-Value Observed: 0.244 
  • Space Group: P 41 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 107.966α = 90
b = 107.966β = 90
c = 153.142γ = 90
Software Package:
Software NamePurpose
CrystalCleardata collection
MOSFLMdata reduction
SCALAdata scaling

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment 

Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2011-10-05
    Type: Initial release
  • Version 1.1: 2012-02-22
    Changes: Database references
  • Version 1.2: 2014-09-24
    Changes: Database references
  • Version 1.3: 2019-07-17
    Changes: Data collection, Refinement description
  • Version 1.4: 2024-02-28
    Changes: Data collection, Database references, Derived calculations